Olesoxime (TRO19622) a small-molecule with a cholesterol-like structure has remarkable neuroprotective properties for motor neurons in cell culture and in rodents. The biopharmaceutical company Trophos initially developed this compound. This medicine is in phase II clinical trial in treating spinal muscular atrophy and in phase I for patients with stable relapsing remitting multiple sclerosis. This drug was also investigated in phase III clinical trial for amyotrophic lateral sclerosis, but it did not demonstrate a significant increase in survival versus placebo and that study was discontinued. Preclinical studies have demonstrated that the olesoxime promoted the function and survival of neurons and other cell types under disease-relevant stress conditions through interactions with the mitochondrial permeability transition pore (mPTP).

Ganefromycins are antibiotics produced by Streptomyces lydicus sp. tanzanius and were considered for use as performance enhancement agents for livestock. Ganefromycins are one of a small group of kirromycin-like elfamycins which lack the pyridone moiety. A series of ganefromycin antibiotics has been isolated and identified in order to establish their biosynthetic relationships to the previously reported ganefromycin α.

Olivomycin is an antitumor glycoside antibiotic that binds to DNA. This drug is used to treat testicular neoplasms, tonsillar tumors and reticulosarcoma with peripheral nodes. In addition, olivomycin was studied for the diagnosis of ureaplasma infection of the sperm.